The concept of the inspection result exceeding standard management was introduced for the first time, which means that the test result is beyond the legal standard and the enterprise internal control standard. Excessive inspection results do not necessarily mean that the sample inspection is not qualified. How can the effervescent tablet tube manufacturer be implemented?
First, the operating procedures for the establishment of inspection results exceeding the limits of the investigation within the company. Laboratory investigation was carried out according to the regulations to confirm whether it was laboratory bias. If it is not the laboratory deviation, the R & D, technology and production personnel should be organized to investigate the production process. It can also be interpreted as two categories: laboratory bias and non laboratory bias.
The laboratory deviation shall investigate any deviation of the test results caused by the factors related to the inspection process,A laboratory survey should be carried out by the professional personnel. The non laboratory deviation refers to the deviation of the test results caused by any other factors except the deviation of the laboratory. The above deviation analysis also standardizes the concrete implementation of the inspection results exceeding the standard for effervescent tablet tube factory.
Vitamin C effervescent tablets are a common vitamin supplement that is very popular among young people. There are many manufacturers of vitamin C effervescent tablets on the market, and the phenomenon of product homogeneity is serious. In this context, the effervescent tube has become the key for pharmaceutical companies to break through the bottleneck of product development.
Product competition is not only the competition of the product itself, but also the competition of the entire company and the competition of brands. When vitamin C effervescent tablets have similar taste and safety, the difference in packaging becomes a direct manifestation of product differentiation. Even two products with the same common name will have different market performance due to differences in packaging.
The effervescent tube is a special pharmaceutical packaging for vitamin C effervescent tablets. The effervescent tablet contains a disintegrant and is easily deteriorated by moisture. In order to ensure the dryness of the tablet, a desiccant made of silica gel and molecular sieve is placed inside the effervescent tube . Different from ordinary medicine bottles, the desiccant is stored on the top of the lid to prevent children from accidentally ingesting. The spiral spring on the lid can protect the tablet from damage due to various external forces.
In order to highlight the differentiation of brands and distinguish competing products, some pharmaceutical companies will use the color, logo, slogan, etc. of the effervescent tube to reflect it. For example, use different caps for different flavors of effervescent tablets, and add eye-catching slogans on the external label. In short, differentiation is a weapon for companies to break homogeneity. Only when there are differences can there be a market, and only then can they gain a place in the competition among the strong players.
Plastic vitamin tube is used in vitamin tablet packaging due to its dry environment. There are silical-gel desiccant and large molecular sieve desiccant in plastic vatimin tube. However, silica-gel desiccant is the only one through FDA and healthy for human.
desiccant cap
spiral desiccant closure
Silica-gel desiccant in vitamin tube is a highly active adsorbent material, which belongs to amorphous material. Silic-gel desiccant of vitamin tube cap insoluble in water, non-toxic and tasteless, chemically stable. According to diameter, silica can be divided into macroporous silica gel, coarse – hole silica gel, type B silicone, fine – hole silica gel. Silica can reuse through rebirth. The main ingredient of silica-gel desiccant is Sio2, for more translucent amorphous, composed of natural mineral processed granular or bead, usually after treatment with sulfuric acid to form, its hard, non-toxic, tasteless, non-corrosive, good chemical stability and thermal stability.
plastic vitamin C tube
Silica-gel desiccant of vitamin tube covers many hydroxyl groups with strong hydrophilicity, at the same time, the surface of silica gel desiccant has many small holes that are not visible to the naked eye, so that its surface area is greatly increased, and the properties of silica gel desiccant decide to become a good desiccant.Desiccant moisture environment as temperature of the shelf life is most suitable for 20 ~ 32 ℃, humidity was 60% ~ 60%, it can reduce the environmental relative humidity to 40%.
Xinfuda as a China major pharmaceutical packaging manufacturer with DMF, which can offer excellent desiccant packaging for vitamin tablets. Plastic vitamin tube adopted silica-gel desiccant to keep dry and the spring on the cap can prevent tablets damaging.
On April 13, April 27, and May 13, following the inactivated vaccine developed by Wuhan Research Institute, Beijing Kexing Zhongwei Biotechnology Co., Ltd., Beijing Institute of Biological Products, Chinese Academy of Medical Sciences Medical Biology The new inactivated vaccines developed by the Institute have successively obtained clinical trial approvals.
‘After the vaccine enters the clinical trial stage, it is necessary for the drug regulatory department to strengthen the supervision of the clinical trial process, scientifically carry out clinical safety and effectiveness evaluation, supervise the applicant to perform the main responsibility, and strengthen the safety information reporting and risk management in the clinical trial process.’ According to Wang Haixue, head of the Clinical Trial Management Office, in order to ensure the quality of clinical trials and protect the rights and interests of subjects, the Center for Drug Evaluation formally issued the “Regarding Strengthening the Clinical Trial of New Coronary Pneumonia Vaccines” The Notice on Trial Safety Information Report and Risk Management clarifies the applicant’s main responsibility for clinical trials, requires the applicant to carry out clinical trials in strict accordance with the clinical trial management specifications and the requirements of clinical trial approval documents, establish a complete pharmacovigilance system, and formulate a complete Risk control measures, strengthen the quality control of clinical research samples, timely report the phased progress of clinical trials, set up a data security monitoring committee, conduct risk communication in a timely manner, and recommend long-term safety observations for subjects.
‘The Clinical Trial Management Office communicates with applicants daily to master vaccine clinical trial progress, case enrollment status and safety information. At the same time, it strengthens communication among vaccine review indication teams, conducts risk analysis and assessment, and establishes an efficient According to incomplete statistics, according to incomplete statistics, according to incomplete statistics, according to incomplete statistics, except for the daily report of clinical trial progress and safety information, according to Wang Haixue, only one new crown vaccine research and development institution/company is taken as an example. In addition, the Center for Drug Evaluation also conducted 14 special communications with the applicant.
In order to strengthen the applicant’s timely and dynamic risk monitoring and evaluation of safety information, the Clinical Trial Management Office of the Center for Drug Evaluation also drafted a report form that summarizes clinical research progress and safety information, and determined a clear, unified and standardized safety information report. Applicants are required to report the number of participants in clinical trials and the status of SAE and SUSAR on a daily basis for the content and format of the trial; and it is recommended to submit phase I and II clinical trial data as soon as possible, in order to timely evaluate vaccine early clinical trial data, and accelerate the promotion and support of vaccine follow-up Development of clinical research.
At the same time, the Center for Drug Evaluation is actively discussing with domestic and foreign experts and industry R&D personnel on the basic conditions for the approval of the new crown vaccine for marketing and the phase III clinical protection efficacy trial design and implementation strategies, in order to reach consensus and obtain relevant information. With the support of all parties, we will make every effort to promote the early listing of the new crown vaccine.
The definition of Nutraceuticals on a global stage is highly divergent. It could refer to products that range from isolated nutrients, dietary supplements, herbal medicines, functional foods, medical/ specific diets and beverages. In India, nutraceuticals and herbal medicinal products fall under the purview of different regulatory bodies, FSSAI, AYUSH or CDSCO, depending on the health claims made and ingredients used.
The Indian nutraceuticals industry is in a growth phase, with several key drivers such as consumer awareness, emphasis on prevention over cure and clinical receptiveness, being some of them.
India also fosters a thriving market for herbal extracts. Much of the traditional medicine practised worldwide can trace its roots to India, and the country is a hot bed for cultivation of herbal plants. The herbal extracts industry is estimated at $1.3 billion, with exports accounting for a sizeable 47 per cent of sales.
India also has the unique advantage of long-standing heritage and knowledge, when it comes to traditional medicines. Equipped with local sourcing and supply of raw materials, herbal extract manufacturers have emerged as highly price competitive in the global markets and have established a strong presence as a preferred supplier in many export markets.
Pharmaceutical and Veterinary Packaging Manufacturer 